ADOCIA Announces its Financial Calendar for 2026
LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.
February 24, 2026 |
Publication of revenue for Q4 2025 |
|
April 21, 2026 |
Publication of 2025 financial statements |
|
May 12, 2026 |
Publication of revenue for Q1 2026 |
|
June 3, 2026 |
Annual shareholders’ meeting |
|
July 23, 2026 |
Publication of revenue for Q2 2026 |
|
September 24, 2026 |
Publication of mid-year financial statements as of June 30, 2026 |
|
October 29, 2026 |
Publication of revenue for Q3 2026 |
In addition to regular meetings with the financial community, investors can also find updated information on the company’s website (www.adocia.com).
All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section “Regulated Information”.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLongTM, a long-acting peptide platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218443649/en/
Adocia
Olivier Soula
CEO
[email protected]
+33 (0)4 72 610 610
www.adocia.com
Ulysse Communication
Adocia Press & Investor Relations
Bruno Arabian
Nicolas Entz
[email protected]
+ 33 (0)6 87 88 47 26
Source: Adocia
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Inside the $63 Million Investment Modernizing Over 1,700 Fort Sill Homes
- Security National Financial Corporation Announces Stock Dividend
- Renters Insurance Tulsa Explained In HelloNation Featuring Insurance Agent Bobby Williamson
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share